详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

PD-1/PD-L1 and immunotherapy for pancreatic cancer

100| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China [2]Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China [3]Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China [4]Clinical Immunology Center, Chinese Academy of Medical Science, Beijing, 100730, China

出处：

DOI：

ISSN：

关键词： PD-1/PD-L1 Immunotherapy Pancreatic cancer Immune resistance Tumour microenvironment

摘要：

Therapy that targets programmed death 1 or programmed death 1 ligand 1 (PD-1/PD-L1), which are known as immune checkpoints, has been recently rapidly developing as oncotherapy for various carcinomas. However, this therapy has a poor effect on the treatment of pancreatic cancer with PD-1/PD-L1 blockade monotherapy. In this review, the development and limitations of anti-PD-1/PD-L1 mono therapy in pancreatic cancer are discussed. We then consider the underlying mechanism of anti-PD-1/PD-Ll monotherapy failure, combination strategies overcoming resistance to anti-PD-1/PD-L1 immunotherapy and the prospect of targeting PD-1/PD-L1 for the immunotherapy of pancreatic cancer. (C) 2017 Elsevier B.V. All rights reserved.

基金：

基金编号： 81272484 2014CB542300 2014BAI09B11 2016-I2M-1-001

语种：

高被引：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 2 区医学

小类 | 2 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学

JCR分区：

出版当年[2015]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 9.1 最新[2023版] 8.3 最新五年平均 5.992 出版当年[2015版] 5.174 出版当年五年平均 5.621 出版前一年[2014版] 6.375 出版后一年[2016版]

第一作者：

第一作者单位： [1]Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China

共同第一作者：

通讯作者：

通讯机构： [*1]1 Shuaifuyuan,Wangfujing St, Beijing 100730, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]PD-1/PD-L1抑制剂在儿童复发难治淋巴瘤中的免疫治疗进展 [2]Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors [3]PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities [4]Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer [5]PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance [6]Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC [7]TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy [8]Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors [9]Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade [10]Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy

PD-1/PD-L1 and immunotherapy for pancreatic cancer $(function () { $("[data-toggle='tooltip']").tooltip(); });

文献详情

相关文献

PD-1/PD-L1 and immunotherapy for pancreatic cancer